Rapport Therapeutics (RAPP) Accumulated Expenses (2024 - 2026)

Rapport Therapeutics (RAPP) has 3 years of Accumulated Expenses data on file, last reported at $4.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $4.0 million, down 35.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (down 35.28% YoY), and the FY2025 annual result was $7.1 million, up 17.18% from the prior year.
• Accumulated Expenses declined to $4.0 million in Q1 2026 per RAPP's latest filing, from $7.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $8.6 million in Q3 2025 and troughed at $1.8 million in Q2 2024.
• A 3-year average of $5.3 million and a median of $6.1 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses surged 73.92% in 2025, then tumbled 35.28% in 2026.
• A 3-year view of Accumulated Expenses shows it stood at $6.1 million in 2024, then climbed by 17.18% to $7.1 million in 2025, then tumbled by 43.31% to $4.0 million in 2026.
• Business Quant data shows RAPP's Accumulated Expenses at $4.0 million in Q1 2026, $7.1 million in Q4 2025, and $8.6 million in Q3 2025.